CASI Pharmaceuticals, Inc.
CASI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | -$0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -15.8% | -21.4% | 42.9% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 39.1% | 59.2% | 63.3% | 58.4% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -122.2% | -63.6% | -55.8% | -110.7% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -137.6% | -79.5% | -95.1% | -121.5% |
| EPS Diluted | -2.56 | -2.02 | -3.01 | -2.69 |
| % Growth | -26.7% | 32.9% | -11.9% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |